3
April 2024
IXICO
plc
("IXICO"
or the "Company")
Imeka
Collaboration Agreement
IXICO plc (AIM: IXI),
the medical imaging advanced analytics company
delivering intelligent insights in neuroscience, announces a collaboration agreement with IMEKA Solutions
Inc. ("Imeka") to provide access to Imeka's suite of services for
white matter1 imaging deployed in Alzheimer's Disease (AD) and Multiple Sclerosis (MS) clinical
trials, amongst other CNS indications.
Imeka's diffusion MRI
algorithms will be made available to IXICO's global biopharma
clients, streamlining access to these tools through a combined
study delivery. With a single contracting line, this
simplifies the procurement process whilst improving access to a
broader suite of white matter imaging AI tools and solutions
delivered by IXICO. White matter imaging is of increasing
interest for neuroinflammation, axonal integrity and myelin
integrity, in particular in AD and MS clinical trials amongst other
CNS indications.
Giulio Cerroni, Chief Executive Officer of IXICO,
commented:
''We are pleased to be partnering with Imeka
to further the understanding of debilitating neurological diseases
through the power of advanced imaging technology, in the hope that
our partnership will bring clarity and accessibility to previously
untapped possibilities of image analysis."
Jean-René Bélanger, Chief Executive Officer of Imeka,
commented:
"We are delighted to contribute to IXICO's outstanding imaging
CRO services. Our collaboration reflects a shared commitment to
integrating advanced imaging technologies into treatment
development. By offering Imeka's expertise into IXICO's, we
anticipate the emergence of new opportunities that will ultimately
enhance patient care and provide significant benefits to patients
and their families."
For
further information please contact:
|
IXICO plc
|
|
|
Giulio Cerroni, Chief Executive
Officer
Grant Nash, Chief Financial
Officer
|
+44
(0)20 3763 7499
|
|
|
|
|
|
|
|
|
| |
1 White matter are
areas of the brain that primarily consists of myelinated axons. In
the brain, white matter is found closer to the centre of the brain,
whereas the outer cortex is mainly grey matter
This is an RNS Reach announcement and the
information contained is not considered to have a significant
impact on management's expectations of the Group's performance. RNS
Reach is an investor communication service aimed at assisting
listed and unlisted (including AIM quoted) companies to distribute
non-regulatory news releases into the public domain. Information
required to be notified under the AIM Rules for Companies, Market
Abuse Regulation or other regulation would be disseminated as an
RNS regulatory announcement and not on RNS Reach.
About IXICO |
Advanced Analytics | Intelligent Insights.
IXICO is dedicated to delivering insights in
neuroscience to help transform the advancement of investigational
therapies for neurological diseases, such as Huntington's disease,
Parkinson's disease and Alzheimer's disease. The
Company's purpose is to advance medicine and human health by
turning data into clinically meaningful information, providing
valuable new insights in neuroscience by supporting pharmaceutical
companies across all phases of CNS clinical research. IXICO's goal
is to be a leading advocate of artificial intelligence in medical
image analysis.
IXICO has developed and deployed
breakthrough data analytics, at scale, through its remote access
technology platform, to improve the return on investment in drug
development and reduce risk and uncertainty in clinical trials for
the Company's pharmaceutical clients.
More information is available
on www.IXICO.com
About
Imeka
Imeka is the global leader in white matter
microstructure imaging, combining advanced MRI processing
capabilities and artificial intelligence to bring novel insights to
the research and clinical communities. The company has been working
with all major pharmaceutical companies developing treatments for
neurodegenerative diseases and is now offering its state-of-the-art
technology to physicians to directly impact patients.
More information is available
on www.imeka.ca
